CHINOOK THERAPEUTICS, INC. (KDNY) [Rocket]

Overview

CHINOOK THERAPEUTICS, INC. (KDNY)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
08/21/2023	15-12G	Form 15-12G - Securities registration termination [Section 12(g)]:
08/17/2023	EFFECT	Form EFFECT - Notice of Effectiveness:
08/11/2023	SC 13D	Farallon Capital Partners, L.P. reports a 9.9% stake in Chinook Therapeutics, Inc.
08/11/2023	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/11/2023	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/11/2023	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/11/2023	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
Revenues	6.1	51.6	0.8	0.0	15.1	17.2	50.7	73.0
Revenue growth	-88.1%	6142.4%		-100.0%	-12.5%	-66.0%	-30.6%	445.1%
Cost of goods sold	12.0	20.1	1.5	0.0	0.0	0.0	0.0	0.0
Gross profit	-5.9	31.5	-0.7	0.0	15.1	17.2	50.7	73.0
Gross margin	-95.6%	61.1%	-82.6%		100.0%	100.0%	100.0%	100.0%
Research and development	141.2	97.0	36.1	17.0	75.8	89.4	87.7	58.6
General and administrative	36.3	31.9	19.1	3.0	36.0	33.8	34.3	27.8
EBITA	-186.6	-91.8	-55.8	-20.0	-96.8	-105.9	-71.3	-13.5
EBITA margin	-3045.2%	-177.7%	-6747.9%		-641.5%	-614.3%	-140.7%	-18.5%
Amortization of intangibles	1.7	1.7	0.4		0.6	0.6	0.5	0.1
EBIT	-188.3	-93.4	-56.2	-20.0	-97.4	-106.5	-71.9	-13.6
EBIT margin	-3073.3%	-181.0%	-6798.9%		-645.4%	-617.5%	-141.8%	-18.6%
Pre-tax income	-183.5	-100.8	-83.6	-46.5	-96.1	-103.2	-69.7	-39.3
Income taxes	4.3	2.1	-2.0	0.0	-0.8	-11.4	21.5	-0.1
Tax rate			2.4%	0.0%	0.8%	11.0%		0.3%
Net income	-187.9	-102.9	-81.6	-46.5	-95.4	-91.9	-91.1	-39.2
Net margin	-3065.7%	-199.4%	-9869.6%		-632.0%	-532.9%	-179.8%	-53.7%

Diluted EPS	($2.92)	($2.26)	($6.20)	($25.48)	($1.21)	($1.26)	($1.40)	($0.88)
Shares outstanding (diluted)	64.4	45.6	13.2	1.8	78.8	72.9	65.2	44.7

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.